152 related articles for article (PubMed ID: 6430210)
21. Chronic GM1 gangliosidosis presenting as dystonia: clinical and biochemical studies in a new case.
Nardocci N; Bertagnolio B; Rumi V; Combi M; Bardelli P; Angelini L
Neuropediatrics; 1993 Jun; 24(3):164-6. PubMed ID: 8355822
[TBL] [Abstract][Full Text] [Related]
22. Clinical and genetic variations in the syndrome of adult GM2 gangliosidosis resulting from hexosaminidase A deficiency.
Argov Z; Navon R
Ann Neurol; 1984 Jul; 16(1):14-20. PubMed ID: 6235771
[TBL] [Abstract][Full Text] [Related]
23. Adult (chronic) GM2 gangliosidosis. Atypical spinocerebellar degeneration in a Jewish sibship.
Rapin I; Suzuki K; Suzuki K; Valsamis MP
Arch Neurol; 1976 Feb; 33(2):120-30. PubMed ID: 175770
[TBL] [Abstract][Full Text] [Related]
24. Intracellular degradation of sulforhodamine-GM1: use for a fluorescence-based characterization of GM2-gangliosidosis variants in fibroblasts and white blood cells.
Agmon V; Khosravi R; Marchesini S; Dinur T; Dagan A; Gatt S; Navon R
Clin Chim Acta; 1996 Mar; 247(1-2):105-20. PubMed ID: 8920231
[TBL] [Abstract][Full Text] [Related]
25. Animal model of human disease: GM2 gangliosidosis.
Pierce KR; Kosanke SD; Bay WW; Bridges CH
Am J Pathol; 1976 May; 83(2):419-22. PubMed ID: 817606
[No Abstract] [Full Text] [Related]
26. Diagnosis of infantile and juvenile forms of GM2 gangliosidosis variant 0. Residual activities toward natural and different synthetic substrates.
Kytzia HJ; Hinrichs U; Sandhoff K
Hum Genet; 1984; 67(4):414-8. PubMed ID: 6436167
[TBL] [Abstract][Full Text] [Related]
27. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
Sango K; McDonald MP; Crawley JN; Mack ML; Tifft CJ; Skop E; Starr CM; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
Nat Genet; 1996 Nov; 14(3):348-52. PubMed ID: 8896570
[TBL] [Abstract][Full Text] [Related]
28. Mutation of the GM2 activator protein in a feline model of GM2 gangliosidosis.
Martin DR; Cox NR; Morrison NE; Kennamer DM; Peck SL; Dodson AN; Gentry AS; Griffin B; Rolsma MD; Baker HJ
Acta Neuropathol; 2005 Nov; 110(5):443-50. PubMed ID: 16200419
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement in feline GM2 gangliosidosis: catabolic effects of human beta-hexosaminidase A.
Rattazzi MC; Appel AM; Baker HJ
Prog Clin Biol Res; 1982; 94():213-20. PubMed ID: 6214798
[No Abstract] [Full Text] [Related]
30. [GM2-Gangliosidosis variant B1 disclosed during adolescence by an isolated multi-systemic involvement of the central and peripheral nervous systems].
Le Coz P; Assouline E; Vanier MT; Goutières F; Mikol J; Woimant F; Pinard JM; Aicardi J; Haguenau M
Rev Neurol (Paris); 1994; 150(1):61-6. PubMed ID: 7801043
[TBL] [Abstract][Full Text] [Related]
31. Assay of ganglioside GM2-N-acetyl-beta-D-galactosaminidase activity in human fibroblasts employing the natural activator protein--diagnosis of variant forms of GM2 gangliosidosis.
Erzberger A; Conzelmann E; Sandhoff K
Clin Chim Acta; 1980 Dec; 108(3):361-8. PubMed ID: 6781795
[TBL] [Abstract][Full Text] [Related]
32. Ganglioside GM2 N-acetyl-beta-D-galactosaminidase activity in cultured fibroblasts of late-infantile and adult GM2 gangliosidosis patients and of healthy probands with low hexosaminidase level.
Conzelmann E; Kytzia HJ; Navon R; Sandhoff K
Am J Hum Genet; 1983 Sep; 35(5):900-13. PubMed ID: 6614006
[TBL] [Abstract][Full Text] [Related]
33. [Identification of GM2-gangliosidosis using an in vitro loading test].
Akhunov VS; Krasnopol'skaia KD
Vopr Med Khim; 1987; 33(4):115-9. PubMed ID: 3116767
[TBL] [Abstract][Full Text] [Related]
34. Clinical and biochemical abnormalities in porcine GM2-gangliosidosis.
Kosanke SD; Pierce KR; Bay WW
Vet Pathol; 1978 Nov; 15(6):685-99. PubMed ID: 108843
[No Abstract] [Full Text] [Related]
35. Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system.
Miklyaeva EI; Dong W; Bureau A; Fattahie R; Xu Y; Su M; Fick GH; Huang JQ; Igdoura S; Hanai N; Gravel RA
Brain Res; 2004 Mar; 1001(1-2):37-50. PubMed ID: 14972652
[TBL] [Abstract][Full Text] [Related]
36. Accumulation of ganglioside Gm2 in cerebrospinal fluid of a patient with the variant AB of infantile Gm2 gangliosidosis.
Pullarkat RK; Reha H; Beratis NG
Pediatrics; 1981 Jul; 68(1):106-8. PubMed ID: 7243492
[TBL] [Abstract][Full Text] [Related]
37. Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.
Nestrasil I; Ahmed A; Utz JM; Rudser K; Whitley CB; Jarnes-Utz JR
Mol Genet Metab; 2018 Feb; 123(2):97-104. PubMed ID: 29352662
[TBL] [Abstract][Full Text] [Related]
38. GM2 gangliosidosis AB variant: clinical and biochemical studies of a Japanese patient.
Sakuraba H; Itoh K; Shimmoto M; Utsumi K; Kase R; Hashimoto Y; Ozawa T; Ohwada Y; Imataka G; Eguchi M; Furukawa T; Schepers U; Sandhoff K
Neurology; 1999 Jan; 52(2):372-7. PubMed ID: 9932959
[TBL] [Abstract][Full Text] [Related]
39. Electroconvulsive therapy treatment of depression in a patient with adult GM2 gangliosidosis.
Renshaw PF; Stern TA; Welch C; Schouten R; Kolodny EH
Ann Neurol; 1992 Mar; 31(3):342-4. PubMed ID: 1386210
[TBL] [Abstract][Full Text] [Related]
40. Movement disorders associated with chronic GM2 gangliosidosis. Case report and review of the literature.
Oates CE; Bosch EP; Hart MN
Eur Neurol; 1986; 25(2):154-9. PubMed ID: 3081350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
